Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Pfizer : Lilly, Pfizer say NGF drug works in back pain too

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2019 | 04:13am EST

Eli Lilly and Pfizer have another positive phase 3 trial for their nerve growth factor-targeting drug tanezumab, showing effective pain relief in chronic lower back pain (CLBP).

The efficacy data back up the findings of two earlier phase 3 trials in osteoarthritis last year, but once again safety concerns that have undermined the NGF inhibitor class for years havent been dispelled by the results.

In the CLBP study, the higher 10mg dose of tanezumab was able to show a statistically significant improvement in pain at 16 weeks compared to placebo, although the lower 5mg dose failed to meet this objective. Full details will be presented at a medical conference later this year.

Turning to the safety data, Lilly and Pfizer reveal that 1.4% of all tanezumab-treated patients suffered rapidly progressive osteoarthritis, compared to 0.1% of the placebo group. There were no cases of osteonecrosis leading to rapid joint destruction (arthropathy), a side effect that prompted the FDA to slap a clinical hold on the entire NGF inhibitor class in 2010.

Nevertheless, rapidly-progressing osteoarthritis seems to be a risk associated with all the NGF inhibitors tested to date, and could be problematic given that these drugs are intended for conditions that effect millions of people.

The class has a lengthy list of discontinued candidates, mainly due to safety issues, including Johnson & John/Amgens fulranumab and candidates from AstraZeneca and AbbVie. Pfizer/Lillys tanezumab along with Regeneron/Tevas fasinumab which reported positive phase 3 results in osteoarthritis last year are the only NGF-targeting drugs that remain in late-stage development.

Regeneron revealed last year it had halted a high-dose arm in its study after a risk-benefit assessment suggested some patients might be at risk of what George Yancopoulos, Regenerons chief scientific officer, had described as rapidly-progressing osteoarthritis.

Pfizer and Lilly have been fairly guarded about the prospects for tanezumab so far, but seem to be getting more optimistic about a path to approval.

We look forward to further analysing these results, and believe the data from this study will support our planned future global regulatory submissions inback pain, said Ken Verburg, tanezumab development team leader at Pfizer.

Pfizer and Lillys development programme for the drug includes several pivotal studies in osteoarthritis, CLBP and cancer pain due to bone metastases, with two further trials in osteoarthritis and CLBP due to report before the end of the year.

The market for drugs that deliver effective pain relief without the risk of side effects and addiction linked to opioid analgesics could be massive, and that is driving the development of the NGF inhibitors despite the risks.

In contrast to opioids, which alter pain perception by targeting opioid receptors, NGF inhibitors block signalling of a pathway activated in response to injury, inflammation, or chronic pain.

(c) International 2006-2019, SANA Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
04:13aPFIZER : Lilly, Pfizer say NGF drug works in back pain too
AQ
02/21PFIZER : Ochsner Health System and Pfizer Partner to Develop Innovative Models f..
AQ
02/21CYTODYN INC. : - Leronlimab reduces by more than 98% human breast cancer metasta..
AQ
02/21PFIZER : and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in ..
AQ
02/20PFIZER : Sales of generic oncology drugs surge
AQ
02/20PFIZER : Pivotal Phase III Data for BAVENCIO (avelumab) Plus INLYTA (axitinib) i..
AQ
02/19RECENT RESEARCH AND THE CURRENT SCEN : Otsuka, astrazeneca, pfizer, eli lilly
AQ
02/19PFIZER : Ochsner Health System and Pfizer Partner to Develop Innovative Models f..
BU
02/19Pfizer Gets European OK for Zirabev Biosimilar to Genentech's Avastin
DJ
02/19PFIZER : Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimil..
BU
More news
Financials ($)
Sales 2019 53 177 M
EBIT 2019 19 894 M
Net income 2019 12 226 M
Debt 2019 29 742 M
Yield 2019 3,42%
P/E ratio 2019 19,37
P/E ratio 2020 16,22
EV / Sales 2019 5,16x
EV / Sales 2020 5,03x
Capitalization 244 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 44,2 $
Spread / Average Target 4,9%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-3.32%244 412
JOHNSON & JOHNSON5.66%363 193
ROCHE HOLDING LTD.13.83%238 215
NOVARTIS7.85%231 004
MERCK AND COMPANY4.48%207 588
ELI LILLY AND COMPANY6.00%127 067